Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung

Anaplastic lymphoma kinase (ALK) gene rearrangements are present in ∼5% of non-small-cell lung cancers (NSCLCs). These rearrangements occur because of a chromosomal inversion within the short arm of Chromosome 2, which results in the formation of the echinoderm microtubule-associated protein-like 4 (EML4)–ALK fusion oncogene. Whereas NSCLC transformation to SCLC is a rare phenomenon described in epidermal growth factor receptor (EGFR) mutant cancers primarily after treatment with targeted therapy, it is exceedingly rare in ALK-rearranged adenocarcinomas. It is currently unclear what the therapeutic significance of the rearrangement is in this transformed tumor as there is a paucity of medical literature describing follow-up care and outcomes of patients in this rare scenario. We describe a unique case in which a patient with ALK-rearranged adenocarcinoma underwent small-cell transformation at a metastatic site with retained ALK rearrangement and was provided clinical follow-up after treatment with second-generation tyrosine kinase inhibiter (TKI) therapy.

[1]  Y. Ichinose,et al.  First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  E. Ma,et al.  Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung , 2012, Acta oncologica.

[3]  M. Pietanza,et al.  The molecular pathogenesis of small cell lung cancer , 2010, Cancer biology & therapy.

[4]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[5]  M. Ladanyi,et al.  Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. , 2010, Clinical lung cancer.

[6]  K. Kasahara,et al.  Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. , 2013, Lung cancer.

[7]  Y. Ichinose,et al.  An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. , 2013, Lung cancer.

[8]  M. Ladanyi,et al.  EGFR mutations in small-cell lung cancers in patients who have never smoked. , 2006, The New England journal of medicine.

[9]  M. Fukuoka,et al.  Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. , 2007, Lung cancer.

[10]  P. Dartevelle,et al.  Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[12]  A. Nicholson,et al.  Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. , 2013, Lung cancer.

[13]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[14]  J. Zhao,et al.  Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature , 2016, Medicine.